Causative factors behind poloxamer 188 (Pluronic F68, Flocor™)-induced complement activation in human sera

This publication has 32 references indexed in Scilit:

• Therapeutic synthetic polymers: a game of Russian roulette?
  Drug Discovery Today, 2002
• Capture of Stealth Nanoparticles by the Body’s Defences
  Critical Reviews in Therapeutic Drug Carrier Systems, 2001
• Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction
  American Heart Journal, 1998
• Interactions of Solutol HS 15 and Cremophor EL with plasma lipoproteins
  The International Journal of Biochemistry & Cell Biology, 1995
• Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro
  Kidney International, 1994
• Activation of Complement by Fluosol Attributable to the Pluronic Detergent Micelle Structure
  Journal of Cardiovascular Pharmacology, 1993
• The interaction of soluble human complement receptor type 1 (sCR1, BRL55730) with human complement component C4
  Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1993
• Reduction of myocardial ischemia during percutaneous transluminal coronary angioplasty with oxygenated Fluosol®
  The American Journal of Cardiology, 1990
• Reduction in the toxicity of a component of an artificial blood substitute by supercritical fluid fractionation
  Transfusion, 1988
• Pulmonary complications after Fluosol administration to patients with life-threatening blood loss
  Critical Care Medicine, 1985